Navigation Links
Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
Date:2/14/2013

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

The study appeared in the Feb. 13 online issue of Oncogene.

The IKBKE gene is part of a family of enzyme complexes involved in increasing cellular inflammation. IKBKE overexpression has been associated with breast and prostate cancers. However, it had not been linked to environmental carcinogen, such as tobacco smoke, until now.

Tobacco smoke is the strongest documented initiator and promoter of lung cancer. The traditional model holds that tobacco components promote carcinogenesis through a process that leads to DNA damage.

Recent studies have shown that tobacco smoke can also promote lung cancer through changes in the pathways that regulate cell proliferation and survival. This study explored identifying and understanding one of the signaling pathways in order to find potential drug targets to treat non-small cell lung cancer.

In this study, IKBKE was found to be induced by two tobacco carcinogens: nicotine and a nicotine-derived nitrosamine ketone found in tobacco smoke. Their findings suggest that IKBKE is a key molecule related to tobacco-induced lung cancer.

"Since IKBKE kinase is induced by tobacco, small molecular inhibitors of IKBKE could have a therapeutic drug potential for lung cancer," explained lead author Jin Q. Cheng, Ph.D., M.D., senior member of the Molecular Oncology Department at Moffitt.

Current treatments for non-small cell lung cancer include surgery, radiotherapy and chemotherapy. However, patients eventually develop resistance to treatment. There is a great need to better understand the molecular mechanism of resistance and develop new gene-targeted therapies that can circumvent resistance, said the authors.

In this study, th
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
2. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
3. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
4. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
5. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
6. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
9. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
10. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
11. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Hands On Mobile ... available. The Spa On Wheels has been transformed into ... from the outside world seems to disappear. The Virtual Tour ... massages, facials, spa parties, corporate events and more. , The ... Spa On Wheels which is actually an overhauled Winnebago. Marla ...
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... Amy Norton HealthDay ... Children born to moms who were exposed to high levels ... risk of developing autism, a U.S. study suggests. Researchers ... between 1990 and 2002, those exposed to the most air ... baby who later developed autism. And exposure during the third ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... , , THURSDAY, Nov. 1 (HealthDay News) -- Heart disease ... for an individual,s brothers or sisters, too, U.S. researchers ... among brothers, the Johns Hopkins University team found. For ... chest pain from blocked arteries, the other is 20 ...
... SACRAMENTO, Calif., Nov. 1 Always Best Care ... California,areas. America,s premier In-Home Care, Assisted Living Placement ... seniors in Granada,Hills/Sherman Oaks can now rely on ... over a decade, a caring relationship has been ...
... Addition to Postal Service Social Awareness Stamp,Series, WASHINGTON, ... next year to help raise awareness about Alzheimer,s disease,as ... John,Potter announced today, on the first day of both ... "With the Alzheimer,s Awareness commemorative stamp, we,ll ask,Americans ...
... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
... program,s launch, study found , , THURSDAY, Nov. 1 (HealthDay ... Part D prescription drug benefit increased the number of ... $32 billion to Medicare, a new study concludes. , ... Health Affairs , the study authors noted that many ...
... a statement,from ADA President Mark J. Feldman:, "The ... Camp (R-MI) for introducing legislation that will help bring ... tribal areas,where too many people lack sufficient access to ... "The Native American Full Access to Dental Care ...
Cached Medicine News:Health News:Siblings Often Share Heart Risks 2Health News:Siblings Often Share Heart Risks 3Health News:Announcing Always Best Care Senior Services Expansion Into the Granada Hills/Sherman Oaks, California Areas 2Health News:Alzheimer's Disease to be Highlighted on Stamp Next Year 2Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:Medicare Drug Plan Cost $32 Billion in 2006 2Health News:Medicare Drug Plan Cost $32 Billion in 2006 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Jan. 28 Some 18-20 million Americans are at ... to 10 percent have been diagnosed.  Studies prove that fatality is ... OSA can be readily and successfully treated. , Historically, OSA ... a technician directly monitoring a patient,s breathing.  Many who suspect they ...
... DIEGO , Jan. 28 Conatus Pharmaceuticals Inc. ... evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin ... of the triple combination will be assessed after up to ... medical need in HCV patients who have not responded to ...
Cached Medicine Technology:NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 2NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 3Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
... Advanced diagnostic capabilities combined with ease ... best product in its class. Ideal for ... a complete system for Uroflowmetry, cystometry, leak ... (8) configurations are available which make the ...
... combined with ease of use make the ... class. Ideal for office or hospital-based urodynamics, ... Uroflowmetry, cystometry, leak point pressure, or urethral ... which make the OM-5 flexible enough to ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... simple: to provide better care for your patients. ... lower urinary tract symptoms (LUTS) includes urodynamics for ... to increases in reimbursement, it now makes financial ... are sending them to someone who does not ...
Medicine Products: